Open Access<p>HDAC1/2 Inhibitor Romidepsin Suppresses DEN-Induced Hepatocellular Carcinogenesis in Mice</p>
Author(s) -
Hara Afaloniati,
Katerina Angelopoulou,
Alexandros Giakoustidis,
Alexandros Hardas,
Athanasios Pseftogas,
Kali Makedou,
Athanasios Gargavanis,
Thomas Goulopoulos,
Stavros Iliadis,
V. N. Papadopoulos,
Apostolos Papalois,
George Mosialos,
Theofilos Poutahidis,
Dimitrios Giakoustidis
Publication year - 2020
Publication title -
oncotargets and therapy
Language(s) - Uncategorized
Resource type - Journals
SCImago Journal Rank - 1.054
H-Index - 60
ISSN - 1178-6930
DOI - 10.2147/ott.s250233
Subject(s) - romidepsin , cancer research , apoptosis , medicine , cancer , liver cancer , pten , hepatocellular carcinoma , biology , pi3k/akt/mtor pathway , histone deacetylase , histone , biochemistry , gene
Hepatocellular carcinoma (HCC) is a frequently diagnosed cancer and a leading cause of cancer-related death worldwide. Its rapid progression, combined with the limited treatment options at late stages, imposes the need for early detection and aggressive intervention. Based on the knowledge that hepatocarcinogenesis is significantly influenced by histone acetylation, we directed our search for novel HCC therapeutics among histone deacetylation inhibitors (HDACi). The aim of the present study was to investigate the effect of HDAC1/2 inhibitor Romidepsin in the well-established mouse model of diethylnitrosamine (DEN)-induced HCC.